<DOC>
	<DOCNO>NCT01294748</DOCNO>
	<brief_summary>The DESSOLVE II clinical trial ass safety performance sirolimus-eluting MiStent treatment improve coronary luminal diameter patient symptomatic ischemic heart disease due discrete de novo lesion native coronary artery .</brief_summary>
	<brief_title>Clinical Investigation MiStent Drug Eluting Stent ( DES ) Coronary Artery Disease</brief_title>
	<detailed_description>The DESSOLVE II clinical trial ass safety performance sirolimus-eluting MiStent compare Endeavor DES treatment improve coronary luminal diameter patient symptomatic ischemic heart disease due discrete de novo lesion native coronary artery .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1 . Age ≥18 ≤85 year ; 2 . Stable/unstable angina pectoris ( Class IIV ) , document ischemia/silent ischemia ; 3 . Planned single , de novo , type A , B1 B2 coronary lesion ; 4 . Target lesion locate native coronary artery ; 5 . Target lesion vessel range 2.5 3.5 mm amenable treatment ( coverage ) 30 mm long stent ; 6 . Target lesion &gt; 50 % diameter stenosis ; 7 . Recent Qwave ( &gt; 72 hour ) nonQwave myocardial infarction ; 8 . Patients eligible PCI ; 9 . Candidate CABG ; 10 . A patient may one additional critical nontarget lesion . 11 . Patient capable providing informed consent willing comply study requirement . 1 . Female patient childbearing potential confirm negative pregnancy test baseline form birth control ; 2 . Recent Qwave MI &lt; 72 hour prior index procedure . 3 . Recent Q nonQwave MI still elevate level cardiac marker ( e.g . CK ; CKMB CK elevate ) ; 4 . LVEF &lt; 30 % ( within previous 6months ) ; 5 . Patients cardiogenic shock ; 6 . CVA TIA within past 6 month ; 7 . Active GI bleeding within past 3 month ; 8 . Any prior anaphylactic reaction contrast agent ; 9 . Chemotherapy within 30days index procedure ; 10 . Receiving oral intravenous immunosuppressive therapy know lifelimiting immunosuppressive autoimmune disease ; 11 . Renal dysfunction ( creatinine &gt; 2.0 mg/dL 177 µmol/L ) ; 12 . Platelet count &lt; 100,000 cells/mm³ &gt; 700,000 cells/mm³ ; 13 . White blood cell count &lt; 3,000 cells/mm3 ; 14 . Hepatic disease ; 15 . Heart transplant recipient ; 16 . Known contraindication DAPT ; 17 . Known hypersensitivity sirolimus , cobaltchromium , medication aspirin , heparin Angiomax ( bivalirudin ) , three follow : clopidogrel bisulfate ( Plavix ) , ticlopidine ( Ticlid ) , Prasugrel ( Effient ) ; 18 . Life expectancy le 12 month ; 19 . Any major medical condition may interfere participation study ; 20 . Patient currently participate investigational drug another device study complete followup primary endpoint , patient planning participate prior complete 12months followup ; 21 . Target vessel treat within 10 mm proximal distal target lesion type PCI within year prior index procedure ; 22 . Planned actual target vessel ( ) treatment unapproved device , directional rotational coronary atherectomy , laser , cut balloon , transluminal extraction catheter prior stent placement ; 23 . Patient previously treat time brachytherapy ; 24 . Planned coronary angioplasty CABG first 9 month index procedure plan intervention within 30days post index procedure ; 25 . Prior PCI nontarget vessel must least 14 day prior study enrollment ; 26 . The intent direct stent target lesion ; 27 . Angiographic Instent restenotic target lesion ; Instent restenotic target lesion ; More one lesion require treatment target vessel ) ; Target vessel diameter &lt; 2.5 mm &gt; 3.5 mm ; Long target lesion amenable treatment 30 mm long stent ; Left main critical disease ( ≥50 % DS ) ; Target lesion locate surgical bypass graft ; Total target vessel occlusion ( TIMI flow grade 01 ) ; Target lesion ostial location ; Target lesion bifurcation involve side branch &gt; 2.5 mm lateral branch also require stenting ; Calcified target lesion anticipate unsuccessful/impracticable predilation ; Target vessel excessive tortuosity proximal angulation ; Thrombus present target vessel ; More one nontarget critical lesion ; Nontarget lesion treat index procedure meet follow criterion : 1 . Located within target vessel ; 2 . Located within bypass graft ; 3 . Left main location ; 4 . Chronic total occlusion 5 . Involves complex bifurcation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Drug-eluting Stent</keyword>
	<keyword>Sirolimus</keyword>
</DOC>